Introduction
============

Oral/oropharyngeal carcinoma accounts for \~2%--3% of the systemic malignant tumor.[@b1-ott-9-3381] Among them, squamous cell carcinoma makes up for \>80% and in poor prognosis.[@b2-ott-9-3381]--[@b4-ott-9-3381] The overall 5-year survival rate is only 50%--60%,[@b5-ott-9-3381],[@b6-ott-9-3381] of which the middle-late 5-year survival rate is \~20%--40%,[@b1-ott-9-3381] but the early 5-year survival rate is as high as 80%.[@b1-ott-9-3381],[@b7-ott-9-3381] Therefore, early diagnosis and treatment are the keys to improve the survival rate and quality of patients with oral/oropharyngeal squamous carcinoma (OSCC/OPSCC).[@b1-ott-9-3381],[@b2-ott-9-3381] In recent years, the research on serum tumor markers (TMs) in the early diagnosis of malignant tumors has aroused widespread concern.[@b7-ott-9-3381],[@b8-ott-9-3381] The TM is a kind of substance, which may be abnormal because of tumor cells-related gene expression or body response to tumor in the process of the occurrence and proliferation of malignant tumor.[@b9-ott-9-3381] It was reported that the levels of serum TMs showed better diagnostic values in partial malignant tumors, for example, α-fetoprotein (AFP) and prostate-specific antigen became the specific TMs of liver cancer and prostate cancer, respectively.[@b10-ott-9-3381],[@b11-ott-9-3381] It has been demonstrated that squamous cell carcinoma antigen (SCCAg), cytokeratin 19 fragment (Cyfra21-1), and carcinoembryonic antigen (CEA) were significantly higher in cervical squamous cell carcinoma, small cell lung cancer, and colorectal carcinoma respectively;[@b12-ott-9-3381]--[@b14-ott-9-3381] the levels of serum Cyfra21-1 and SCCAg were significantly higher in partial patients with head and neck squamous cell carcinoma,[@b15-ott-9-3381],[@b16-ott-9-3381] suggesting that these serum TMs might have better clinical value in the screening and diagnosis of the tumor. So far, there is still a lack of any simple or effective method to screen and diagnose patients with OSCC/OPSCC. Since the levels of the serum TMs are different among different malignant tumors, six kinds of serum TMs which were commonly used in clinics at present, including Cyfra21-1, SCCAg, ferritin, CEA, carbohydrate antigen 19-9 (CA19-9), and AFP were selected for this study.[@b10-ott-9-3381],[@b17-ott-9-3381]--[@b20-ott-9-3381] The aim of this study was to measure the levels of serum Cyfra21-1, SCCAg, ferritin, CEA, CA19-9, and AFP in newly diagnosed patients with OSCC/OPSCC, to compare them with those of oral benign tumor and healthy persons, to analyze the sensitivities, specificities, and accuracies of various TMs in the diagnosis of patients with OSCC/OPSCC, and to investigate their diagnostic values in patients with OSCC/OPSCC, so as to guide in clinical diagnosis and treatment.

Materials and methods
=====================

Research objects
----------------

Source of patients: One hundred and sixty-nine cases of newly diagnosed patients with OSCC/OPSCC in the Department of Oral and Maxillofacial Surgery in the First Affiliated Hospital of Chongqing Medical University were chosen from January 2013 to January 2015, including 116 males and 53 females. The average age was 53.95 years. The TNM classification and clinical stage were determined based on the 7th edition of the Union for International Cancer Control standards.[@b15-ott-9-3381] The 169 OSCC/OPSCC cases included 17 cases of stage I, 40 cases of stage II, 61 cases of stage III, and 51 cases of stage IV. All patients were confirmed by pathological examination, did not receive radiotherapy, chemotherapy, or other treatments. The patients had no malignant tumor in other positions. The data are shown in [Table 1](#t1-ott-9-3381){ref-type="table"}. Benign tumor control group: 86 cases of oral benign tumor patients admitted in the hospital were chosen at the same time, including 56 males and 30 females, the average age was 51.35 years. Among them, 25 cases suffered from gingival tumor, 21 cases suffered from papilloma, 20 cases suffered from vascular tumor, 14 cases suffered from benign small salivary gland tumor, and six cases suffered from adamantoblastoma. Healthy control group: 30 cases received the routine physical examination, including 19 males and eleven females; the average age was 51.83 years. They had no systemic disease.

This study was approved by the Biomedicine Ethics Committee of the First Affiliated Hospital of Chongqing Medical University. All patients signed the informed consents.

Methods
-------

Venous blood samples (2 mL) were collected from all fasting patients between 7.00 and 8.00 am, immediately placed in 5 mL anticoagulated antisolvent sterile tube (CDRICH Science and Technology, Chengdu, Sichuan, People's Republic of China), and centrifuged (3,500 rpm) for 10 minutes at room temperature. The serum was separated and measured automatically using electrochemiluminescence immunoassay by Roche Elecsys 2010 analyzer (Roche, Basel, Switzerland).

Statistical analyses
--------------------

The data were processed using SPSS 21.0 (IBM Corporation, Armonk, NY, USA) statistical software and accorded with abnormal distribution by Shapiro--Wilk method. The measurement data were shown with median and analyzed using Kruskal--Wallis nonparametric rank sum test. The comparison among groups was shown with Mann--Whitney *U* test. The enumeration data were shown with percentage and tested with *χ*^2^ test. The receiver operating characteristic curve analysis was performed. The diagnostic cutoff levels, sensitivities, specificities, and accuracies of various TMs were calculated. Sensitivity = (true positive)/(true positive +false negative) ×100%; specificity = (true negative)/(true negative +false positive) ×100%; accuracy = (true positive + true negative)/(true positive + false negative +true negative +false positive) ×100%.[@b13-ott-9-3381],[@b21-ott-9-3381] A *P*-value of \<0.05 was considered significant.

Results
=======

Basic information for patients
------------------------------

There was no significant difference in the mean age or sex among the three groups (*P*\>0.05). Patients among the three groups were comparable.

Serum levels of Cyfra21-1, SCCAg, ferritin, CEA, CA19-9, and AFP in each group
------------------------------------------------------------------------------

The levels of serum Cyfra21-1, SCCAg, ferritin, CEA, CA19-9, and AFP in all patients are shown in [Table 2](#t2-ott-9-3381){ref-type="table"}. The levels of serum Cyfra21-1, SCCAg, ferritin, and CEA in patients with OSCC/OPSCC were significantly higher than those of the benign tumor group and healthy control group (*P*\<0.05). The benign tumor group and healthy control group showed no significant difference (*P*\>0.05). No significant difference in the levels of serum CA19-9 and AFP was observed among patients with OSCC/OPSCC, benign tumor group, and healthy group (*P*\>0.05).

The patients with OSCC/OPSCC in the early stage (stage I + II) and middle-late stage (stage III + IV) were further compared and analyzed. The result demonstrated that the levels of serum Cyfra21-1, SCCAg, ferritin, and CEA in patients with middle-late OSCC/OPSCC were significantly higher than those of patients with early OSCC/OPSCC, benign tumor group, and healthy control group (*P*\<0.05). In the patients with early OSCC/OPSCC, only the level of serum Cyfra21-1 was significantly higher than that of benign tumor group and healthy control group (*P*\<0.05); the levels of serum SCCAg, ferritin, and CEA showed no significant difference among the three groups (*P*\>0.05). No significant difference in the levels of serum CA19-9 and AFP was observed among patients with early, middle-late OSCC/OPSCC, benign tumor group, and healthy control group (*P*\>0.05), suggesting that CA19-9 and AFP had no diagnostic value for patients with OSCC/OPSCC.

Diagnostic cutoff levels, sensitivities, specificities, and accuracies of serum TMs for patients with OSCC/OPSCC
----------------------------------------------------------------------------------------------------------------

The receiver operating characteristic of serum Cyfra21-1, SCCAg, ferritin, and CEA levels in OSCC/OPSCC patients are shown in [Figure 1](#f1-ott-9-3381){ref-type="fig"}. The diagnostic cutoff levels, sensitivities, specificities, and accuracies of serum TMs in patients with OSCC/OPSCC are shown in [Table 3](#t3-ott-9-3381){ref-type="table"}. The results demonstrated that the specificity of Cyfra21-1 was the highest, significantly higher than that of SCCAg, ferritin, and CEA (*P*\<0.05). The specificity of ferritin was the lowest, significantly lower than that of Cyfra21-1, SCCAg, and CEA (*P*\<0.05). There was no significant difference between the specificities of SCCAg and CEA (*P*\>0.05). The sensitivities of SCCAg and ferritin were significantly higher than those of Cyfra21-1 and CEA (*P*\<0.05). The sensitivities showed no significant difference between SCCAg and ferritin, and between Cyfra21-1 and CEA (*P*\>0.05). The accuracies showed no significant difference among Cyfra21-1, SCCAg, ferritin, and CEA (*P*\>0.05).

Discussion
==========

Serum TM has shown great developmental prospect for the screening and diagnosis of malignant tumor.[@b7-ott-9-3381],[@b8-ott-9-3381] There were a few serum TMs aiming for the screening and diagnosis of patients with OSCC/OPSCC. The common six serum TMs were detected simultaneously first in this study, so as to analyze their diagnostic value for OSCC/OPSCC. The overall results suggested that the levels of serum CA19-9 and AFP showed no significant difference between patients with OSCC/OPSCC, benign tumor group, and healthy control group. So CA19-9 and AFP had no diagnostic value for patients with OSCC/OPSCC. The levels of serum Cyfra21-1, SCCAg, ferritin, and CEA were significantly increased in patients with OSCC/OPSCC, suggesting that they had a certain diagnostic value for patients with OSCC/OPSCC.

The ideal serum TMs should have higher sensitivity and specificity at the same time. Higher sensitivity often leads to lower specificity, and vice versa. Therefore, it is important to rationally confirm the diagnostic cutoff levels of the TMs. In this study, the optimal diagnostic cutoff level, corresponding sensitivity, and specificity of the TMs were obtained by receiver operating characteristic analysis. The research results showed that the sensitivities of SCCAg and ferritin were the highest and showed no significant difference. The specificities of SCCAg and ferritin were 68.10% and 40.52%, respectively; the specificity of SCCAg was significantly higher than that of ferritin. Therefore, SCCAg had higher diagnostic value for patients with OSCC/OPSCC than that of ferritin. In the study, the specificity of Cyfra21-1 was the highest (81.03%), the sensitivity was 60.36% and showed no significant difference compared to CEA. Overall, Cyfra21-1 and SCCAg had higher sensitivity and specificity. Therefore, the diagnostic values of Cyfra21-1 and SCCAg were superior to those of other TMs for patients with OSCC/OPSCC.

Cyfra21-1 is a soluble fragment of cytokeratin19 (CK19). CK19 fragment exists in the form of oligomer under normal circumstances. Its content is extremely low. If carcinogenesis occurs, the carcinoma cells could release Cyfra21-1 soluble fragments into blood circulation.[@b15-ott-9-3381] Zhong et al[@b22-ott-9-3381] reported that the sensitivity and specificity of Cyfra21-1 were 57% and 96.4% in patients with OSCC/OPSCC measured by enzyme-linked immunosorbent assay. The electrochemiluminescence immunoassay assay showed that the sensitivity and specificity of Cyfra21-1 were 60.36% and 81.03% in patients with OSCC/OPSCC in this study. The difference might be caused by different detection methods. Recently, Wang et al[@b23-ott-9-3381] reported that the accuracy of serum Cyfra21-1 by enzyme-linked immunosorbent assay was superior to that of electrochemiluminescence immunoassay. In our study, patients with OSCC/OPSCC were divided into the early- and middle-late stage groups. The result showed that the level of serum Cyfra21-1 in patients with early OSCC/OPSCC was significantly higher than that of benign tumor group and healthy control group, suggesting that Cyfra21-1 had better clinical value in the screening and diagnosis of patients with early OSCC/OPSCC.

SCCAg is a subunit of squamous epithelial cell associated antigen TA-4, which is separated from cervical squamous epithelial cells.[@b16-ott-9-3381] Kimura et al[@b24-ott-9-3381] demonstrated that the level of serum SCCAg was increased in esophageal squamous cell carcinoma, anal squamous carcinoma, lung squamous cell carcinoma, and head and neck squamous cell carcinoma, which might have an auxiliary diagnostic value on the tumor. Feng et al[@b25-ott-9-3381] showed that the concentration of serum SCCAg in oral squamous cell carcinoma patients was significantly higher than that of healthy control group; the sensitivity and specificity of SCCAg for oral squamous cell carcinoma were 51.40% and 73.60%, respectively. The results of this study showed that the sensitivity and specificity of SCCAg were 73.37% and 68.10% in patients with OSCC/OPSCC. Further analysis showed that although the level of serum SCCAg in patients with OSCC/OPSCC was significantly higher than that of benign tumor group and healthy control group, the level of serum SCCAg showed no significant difference between patients with early OSCC/OPSCC, benign tumor group, and healthy control group, suggesting that the diagnostic value of SCCAg was poorer in patients with early OSCC/OPSCC.

Conclusion
==========

In summary, among Cyfra21-1, SCCAg, ferritin, CEA, CA19-9, and AFP six serum TMs, Cyfra21-1 and SCCAg had higher sensitivity and specificity at the same time, their diagnoses for patients with OSCC/OPSCC were superior to those of other TMs, Cyfra21-1 had better clinical value for patients with early OSCC/OPSCC, and CA19-9 and AFP had no auxiliary diagnostic value for patients with OSCC/OPSCC.
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![ROC of serum Cyfra21-1, SCCAg, ferritin, and CEA for patients with OSCC/OPSCC.\
**Abbreviations:** CEA, carcinoembryonic antigen; Cyfra21-1, cytokeratin 19 fragment; OSCC/OPSCC, oral/oropharyngeal squamous carcinoma; ROC, receiver operating characteristic; SCCAg, squamous cell carcinoma antigen.](ott-9-3381Fig1){#f1-ott-9-3381}

###### 

Clinical conditions of patients with oral/oropharyngeal squamous cell carcinoma

  ---------------------------------------------------------------------------------------------------
  Position                  Clinical stages   Case number\   Average age\                     
                                              (%)            (years)                          
  ------------------------- ----------------- -------------- -------------- ---- ------------ -------
  Tongue carcinoma          10                18             16             11   55 (32.54)   54.67

  Cheek carcinoma           3                 5              20             11   39 (23.08)   52.13

  Oropharyngeal carcinoma   1                 6              11             13   31 (18.34)   53.61

  Mouth foor carcinoma      2                 2              7              6    17 (10.06)   57.82

  Gingival carcinoma        0                 5              2              7    14 (8.28)    54.29

  Palate carcinoma          0                 2              2              3    7 (4.14)     53.29

  Lip carcinoma             1                 2              3              0    6 (3.55)     49.83

  Total                     17                40             61             51   169 (100)    53.95
  ---------------------------------------------------------------------------------------------------

###### 

Levels of tumor markers in patients with oral/oropharyngeal squamous cell carcinoma, benign tumor, and healthy control group (M)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Groups                                       Cyfra21-1\                                          SCCAg\                                            Ferritin\                                           CEA\                                              CA19-9\   AFP\
                                               (ng/mL)                                             (ng/mL)                                           (ng/mL)                                             (ng/mL)                                           (µ/mL)    (ng/mL)
  -------------------------------------------- --------------------------------------------------- ------------------------------------------------- --------------------------------------------------- ------------------------------------------------- --------- ---------
  Oral/oropharyngeal squamous cell carcinoma   2.39                                                0.90                                              200.80                                              6.79                                              10.36     3.01

  Stage I + II                                 2.14                                                0.73                                              150.10                                              2.10                                              9.74      2.89

  Stage III + IV                               2.54                                                1.06                                              234.85                                              2.94                                              10.52     3.03

  Benign tumor                                 1.61[\*\*](#tfn2-ott-9-3381){ref-type="table-fn"}   0.61[\*](#tfn3-ott-9-3381){ref-type="table-fn"}   154.65[\*](#tfn3-ott-9-3381){ref-type="table-fn"}   1.87[\*](#tfn3-ott-9-3381){ref-type="table-fn"}   8.72      2.79

  Healthy persons                              1.39[\*\*](#tfn2-ott-9-3381){ref-type="table-fn"}   0.60[\*](#tfn3-ott-9-3381){ref-type="table-fn"}   113.49[\*](#tfn3-ott-9-3381){ref-type="table-fn"}   1.48[\*](#tfn3-ott-9-3381){ref-type="table-fn"}   10.33     2.73

  *P*~1~                                       \<0.001                                             \<0.001                                           \<0.001                                             \<0.001                                           0.082     0.585

  *P*~2~                                       \<0.001                                             \<0.001                                           \<0.001                                             \<0.001                                           0.149     0.632

  *P*~3~                                       0.043                                               \<0.001                                           0.002                                               \<0.001                                           --        --

  *P*~4~                                       \<0.001                                             0.981                                             0.964                                               0.430                                             --        --

  *P*~5~                                       \<0.001                                             0.953                                             0.059                                               0.054                                             --        --

  *P*~6~                                       \<0.001                                             \<0.001                                           \<0.001                                             \<0.001                                           --        --

  *P*~7~                                       \<0.001                                             \<0.001                                           \<0.001                                             \<0.001                                           --        --

  *P*~8~                                       0.170                                               0.934                                             0.050                                               0.155                                             --        --
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** The data were analyzed using Kruskal--Wallis nonparametric rank sum test, the comparison among groups was performed using Mann--Whitney *U* test. The measurement data were analyzed using M. *P*~1~ was the comparison result between patients with OSCC/OPSCC, benign tumor group, and healthy group. *P*~2~ was the comparison result between early oral/oropharyngeal squamous cell carcinoma (stage I + II) group, patients with middle-late OSCC/OPSCC (stage III + IV), benign tumor group, and healthy people. *P*~3~ was the comparison result between early and patients with middle-late OSCC/OPSCC. *P*~4~ was the comparison result between the early group and benign tumor group. *P*~5~ was the comparison result between the early stage group and health control group. *P*~6~ was the comparison result between the middle-late group and benign tumor group. *P*~7~ was the comparison result between the middle-late group and healthy control group. *P*~8~ was the comparison result between the benign tumor group and healthy group.

showed comparison with the early group, *P*-value \<0.05;

showed comparison with the middle-advanced stage, *P*-value \<0.05.

**Abbreviations:** AFP, α-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; Cyfra21-1, cytokeratin 19 fragment; M, median; *P*, patients; OSCC/OPSCC, oral/oropharyngeal squamous carcinoma; SCCAg, squamous cell carcinoma antigen.

###### 

Diagnostic cutoff levels, sensitivities, specificities, and accuracies of Cyfra21-1, SCCAg, ferritin, CEA, CA19-9, and AFP in oral/oropharyngeal squamous cell carcinoma

  Items       Diagnostic cutoff levels   Sensitivity %   Specificity %   Accuracy %
  ----------- -------------------------- --------------- --------------- ------------
  Cyfra21-1   2.17                       60.36           81.03           68.77
  SCCAg       0.72                       73.37           68.10           71.23
  Ferritin    109.95                     81.66           40.52           64.91
  CEA         1.99                       66.27           61.21           64.21
  *P*-value   --                         \<0.001         \<0.001         0.236

**Notes:** "--" shows no corresponding value. Diagnostic cutoff levels were calculated from the corresponding value of a point in the ROC curve, where the sum of the sensitivities and specificities was the largest value.

**Abbreviations:** AFP, α-fetoprotein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; Cyfra21-1, cytokeratin 19 fragment; SCCAg, squamous cell carcinoma antigen; ROC, receiver operating characteristic.
